{"transactions":[{"id":707444,"issuer":{"id":6943,"kind":"organization","name":"Gain Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-17T12:33:09.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.68,"expiration_date":"2036-07-15","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-26-084439","document":"tm2620629-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926084439/tm2620629-6_4seq1.xml","form_type":"4"}},{"id":801273,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-24T20:19:14.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":false,"shares":3542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":155833,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":3542},"source":{"system":"sec-edgar","filing":"0001120478-26-000013","document":"form4-04242026_080410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000013/form4-04242026_080410.xml","form_type":"4"}},{"id":801272,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-24T20:19:14.000Z","date":"2026-04-23","kind":"exercise","planned":false,"acquired":true,"shares":3542,"price":4.38,"value":15513.96,"ownership":{"direct":true},"balance_after":36575,"source":{"system":"sec-edgar","filing":"0001120478-26-000013","document":"form4-04242026_080410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000013/form4-04242026_080410.xml","form_type":"4"}},{"id":870291,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:44:53.000Z","date":"2026-03-01","kind":"exercise","planned":false,"acquired":false,"shares":3542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":159375,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":3542},"source":{"system":"sec-edgar","filing":"0001120478-26-000011","document":"form4-03032026_090347.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000011/form4-03032026_090347.xml","form_type":"4"}},{"id":870290,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:44:53.000Z","date":"2026-03-01","kind":"exercise","planned":false,"acquired":true,"shares":3542,"price":4.38,"value":15513.96,"ownership":{"direct":true},"balance_after":33033,"source":{"system":"sec-edgar","filing":"0001120478-26-000011","document":"form4-03032026_090347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000011/form4-03032026_090347.xml","form_type":"4"}},{"id":894407,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T21:38:22.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":110000,"derivative":{"exercise_price":19.63,"expiration_date":"2036-02-16","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001120478-26-000009","document":"form4-02192026_090219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000009/form4-02192026_090219.xml","form_type":"4"}},{"id":922831,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:23:00.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":3541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":162917,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":3541},"source":{"system":"sec-edgar","filing":"0001120478-26-000007","document":"form4-02032026_090256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000007/form4-02032026_090256.xml","form_type":"4"}},{"id":922830,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T21:23:00.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":3541,"price":4.38,"value":15509.58,"ownership":{"direct":true},"balance_after":29491,"source":{"system":"sec-edgar","filing":"0001120478-26-000007","document":"form4-02032026_090256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000007/form4-02032026_090256.xml","form_type":"4"}},{"id":934599,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T21:20:56.000Z","date":"2026-01-16","kind":"exercise","planned":false,"acquired":false,"shares":3542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":166458,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":3542},"source":{"system":"sec-edgar","filing":"0001120478-26-000005","document":"form4-01212026_090153.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000005/form4-01212026_090153.xml","form_type":"4"}},{"id":934598,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-21T21:20:56.000Z","date":"2026-01-16","kind":"exercise","planned":false,"acquired":true,"shares":3542,"price":4.38,"value":15513.96,"ownership":{"direct":true},"balance_after":25950,"source":{"system":"sec-edgar","filing":"0001120478-26-000005","document":"form4-01212026_090153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000005/form4-01212026_090153.xml","form_type":"4"}},{"id":938714,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.  Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award."}],"balance_after":92587,"derivative":{"exercise_price":8.39,"expiration_date":"2034-04-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938713,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":1923,"price":21.0808,"value":40538.3784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.15 per share, inclusive."}],"balance_after":22408,"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938712,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":11663,"price":20.5392,"value":239548.6896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $21.02 per share, inclusive."}],"balance_after":24331,"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938711,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":4440,"price":19.4526,"value":86369.544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.86 per share, inclusive."}],"balance_after":35994,"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938710,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":8974,"price":18.4278,"value":165371.0772,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4."}],"balance_after":40434,"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":938709,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:22:20.000Z","date":"2026-01-13","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":8.39,"value":226530.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024."}],"balance_after":49408,"source":{"system":"sec-edgar","filing":"0001120478-26-000003","document":"form4-01152026_090117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000112047826000003/form4-01152026_090117.xml","form_type":"4"}},{"id":948258,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T00:27:10.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":5.65,"exercise_date":"2027-01-02","expiration_date":"2036-01-02","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-26-005023","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000119312526005023/ownership.xml","form_type":"4"}},{"id":1062810,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-19T20:01:23.000Z","date":"2025-08-18","kind":"exercise","planned":false,"acquired":false,"shares":17557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":1.09,"exercise_date":"2021-04-01","expiration_date":"2031-03-30","underlying":"Common Stock","underlying_shares":17557},"source":{"system":"sec-edgar","filing":"0001641172-25-024820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000164117225024820/ownership.xml","form_type":"4"}},{"id":1062809,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2025-08-19T20:01:23.000Z","date":"2025-08-18","kind":"exercise","planned":false,"acquired":true,"shares":17557,"price":1.09,"value":19137.13,"ownership":{"direct":true},"balance_after":27557,"source":{"system":"sec-edgar","filing":"0001641172-25-024820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000164117225024820/ownership.xml","form_type":"4"}},{"id":1101984,"issuer":{"id":6943,"kind":"organization","name":"Gain Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-25T21:30:14.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments commencing on July 24, 2025, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.79,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001641172-25-016536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819411/000164117225016536/ownership.xml","form_type":"4"}},{"id":1247495,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-26T02:30:05.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant."}],"balance_after":5000,"derivative":{"exercise_price":5.97,"expiration_date":"2035-02-25","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000950170-25-027253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095017025027253/ownership.xml","form_type":"4"}},{"id":1256857,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T21:19:02.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":170000,"derivative":{"exercise_price":4.38,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001415889-25-004859","document":"form4-02202025_090258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000141588925004859/form4-02202025_090258.xml","form_type":"4"}},{"id":1316423,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-04T02:31:12.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant."}],"balance_after":5000,"derivative":{"exercise_price":5.73,"exercise_date":"2026-01-01","expiration_date":"2035-01-01","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000950170-25-001571","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095017025001571/ownership.xml","form_type":"4"}},{"id":1469120,"issuer":{"id":6943,"kind":"organization","name":"Gain Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-27T01:30:07.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments commencing on July 24, 2024, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.29,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-24-025338","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819411/000149315224025338/ownership.xml","form_type":"4"}},{"id":1675768,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-19T23:30:28.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant."}],"balance_after":5000,"derivative":{"exercise_price":7.41,"exercise_date":"2025-01-01","expiration_date":"2034-01-01","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001493152-24-003110","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000149315224003110/ownership.xml","form_type":"4"}},{"id":1844592,"issuer":{"id":6943,"kind":"organization","name":"Gain Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T20:38:35.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments commencing on July 23, 2023, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":10500,"derivative":{"exercise_price":4.5,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001209191-23-039723","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819411/000120919123039723/doc4.xml","form_type":"4"}},{"id":2069633,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2023-01-04T13:30:17.000Z","date":"2023-01-03","kind":"purchase","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reporting Person purchased 10,000 shares of Common Stock and an accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant."}],"balance_after":5000,"derivative":{"exercise_price":7.5,"exercise_date":"2023-01-03","expiration_date":"2025-01-03","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001493152-23-000221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000149315223000221/ownership.xml","form_type":"4"}},{"id":2069632,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2023-01-04T13:30:17.000Z","date":"2023-01-03","kind":"purchase","acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reporting Person purchased 10,000 shares of Common Stock and an accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001493152-23-000221","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000149315223000221/ownership.xml","form_type":"4"}},{"id":2153014,"issuer":{"id":6943,"kind":"organization","name":"Gain Therapeutics, Inc."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-09-22T20:10:45.000Z","date":"2022-09-20","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests fully on the day before the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer."}],"balance_after":10500,"derivative":{"exercise_price":3.5,"expiration_date":"2032-09-20","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001209191-22-051010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819411/000120919122051010/doc4.xml","form_type":"4"}},{"id":2161576,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-09-12T21:00:41.000Z","date":"2022-09-09","kind":"grant","acquired":true,"shares":37600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months."}],"balance_after":37600,"derivative":{"exercise_price":0.6,"expiration_date":"2032-09-09","underlying":"Common Stock","underlying_shares":37600},"source":{"system":"sec-edgar","filing":"0001104659-22-099286","document":"tm2225655-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000110465922099286/tm2225655-2_4seq1.xml","form_type":"4"}},{"id":2566573,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-09-17T20:17:32.000Z","date":"2021-08-19","kind":"grant","acquired":true,"shares":38135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares shall vest on the first anniversary of August 19, 2021, and the remaining shares shall vest on an equal monthly basis over the following 36 months."}],"balance_after":38135,"derivative":{"exercise_price":3.36,"expiration_date":"2031-08-19","underlying":"Common Stock","underlying_shares":38135},"source":{"system":"sec-edgar","filing":"0001104659-21-116925","document":"tm2127926-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000110465921116925/tm2127926-3_4seq1.xml","form_type":"4"}},{"id":2661930,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-21T15:03:22.000Z","date":"2021-06-18","kind":"purchase","acquired":true,"shares":8000,"price":4.75,"value":38000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The power of attorney under which this form was signed is on file with the Commission."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001104659-21-083253","document":"tm2120227-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000110465921083253/tm2120227-1_4seq1.xml","form_type":"4"}},{"id":2738840,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-27T20:02:29.000Z","date":"2021-04-26","kind":"purchase","acquired":true,"shares":12000,"price":5,"value":60000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The power of attorney under which this form was signed is on file with the Commission."}],"balance_after":22000,"source":{"system":"sec-edgar","filing":"0001104659-21-055580","document":"tm2114321-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000110465921055580/tm2114321-2_4seq1.xml","form_type":"4"}},{"id":3033561,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-09-11T21:20:58.000Z","date":"2020-09-09","kind":"grant","acquired":true,"shares":14634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares shall vest on the first anniversary of September 9, 2020, and the remaining shares shall vest on an equal monthly basis over the following 36 months."}],"balance_after":14634,"derivative":{"exercise_price":8.8,"expiration_date":"2030-09-09","underlying":"Common Stock","underlying_shares":14634},"source":{"system":"sec-edgar","filing":"0001104659-20-104493","document":"tm2030658d4_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000110465920104493/tm2030658d4_4.xml","form_type":"4"}},{"id":3164100,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-04T18:18:27.000Z","date":"2020-04-30","kind":"purchase","acquired":true,"shares":10000,"price":6,"value":60000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The power of attorney under which this form was signed is on file with the Commission."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001104659-20-056110","document":"tm2018429-2_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000110465920056110/tm2018429-2_form4.xml","form_type":"4"}},{"id":3165670,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-01T21:11:29.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001193805-20-000551","document":"e619597_4a-goldstein.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000119380520000551/e619597_4a-goldstein.xml","form_type":"4/A","original_submission_date":"2020-03-03"}},{"id":3234341,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-04T00:11:09.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":2.915,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-20-000291","document":"e619425_4-goldstein.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000119380520000291/e619425_4-goldstein.xml","form_type":"4"}},{"id":3234340,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-04T00:11:09.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"), which will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"), which will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001193805-20-000291","document":"e619425_4-goldstein.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000119380520000291/e619425_4-goldstein.xml","form_type":"4"}},{"id":3461238,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-07-17T00:33:39.000Z","date":"2019-07-12","kind":"grant","acquired":true,"shares":227330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the total shares subject to the option shall vest monthly over three years."}],"balance_after":227330,"derivative":{"exercise_price":5.39,"expiration_date":"2029-07-12","underlying":"Common stock","underlying_shares":227330},"source":{"system":"sec-edgar","filing":"0001387131-19-005129","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000138713119005129/ownership.xml","form_type":"4"}},{"id":3593809,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-03-15T21:01:58.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option terminates on the earlier of (i) March 13, 2029 and (ii) the one-year anniversary of the reporting person's ceasing to serve as a director of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":3.89,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193805-19-000296","document":"e618305_4-goldstein.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000119380519000296/e618305_4-goldstein.xml","form_type":"4"}},{"id":3884338,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-25T21:02:05.000Z","date":"2018-06-22","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option terminates on the earlier of (i) June 22, 2028 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer."}],"balance_after":17500,"derivative":{"exercise_price":4.91,"expiration_date":"2028-06-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001193805-18-000904","document":"e618129_4-goldstein.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000119380518000904/e618129_4-goldstein.xml","form_type":"4"}},{"id":3900526,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T21:08:02.000Z","date":"2018-06-06","kind":"exercise","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. (\"Aisling\"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":17.75,"exercise_date":"2017-06-09","expiration_date":"2026-06-09","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001179110-18-008309","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911018008309/edgar.xml","form_type":"4"}},{"id":3900525,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T21:08:02.000Z","date":"2018-06-06","kind":"exercise","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. (\"Aisling\"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":14.42,"exercise_date":"2015-05-15","expiration_date":"2024-05-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001179110-18-008309","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911018008309/edgar.xml","form_type":"4"}},{"id":3900524,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-08T21:08:02.000Z","date":"2018-06-06","kind":"other","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. (\"Aisling\"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein."}],"balance_after":47,"source":{"system":"sec-edgar","filing":"0001179110-18-008309","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911018008309/edgar.xml","form_type":"4"}},{"id":3900523,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-08T21:08:02.000Z","date":"2018-06-06","kind":"other","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. (\"Aisling\"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein."}],"balance_after":8047,"source":{"system":"sec-edgar","filing":"0001179110-18-008309","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911018008309/edgar.xml","form_type":"4"}},{"id":3900522,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-08T21:08:02.000Z","date":"2018-06-06","kind":"exercise","acquired":true,"shares":8000,"price":17.75,"value":142000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. (\"Aisling\"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein."}],"balance_after":13047,"source":{"system":"sec-edgar","filing":"0001179110-18-008309","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911018008309/edgar.xml","form_type":"4"}},{"id":3900521,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-08T21:08:02.000Z","date":"2018-06-06","kind":"exercise","acquired":true,"shares":5000,"price":14.42,"value":72100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. (\"Aisling\"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein."}],"balance_after":5047,"source":{"system":"sec-edgar","filing":"0001179110-18-008309","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911018008309/edgar.xml","form_type":"4"}},{"id":3917570,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-25T20:18:22.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in full on the earlier of (i) May 23, 2019 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2018."}],"balance_after":10100,"derivative":{"exercise_price":38.32,"expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001179110-18-007561","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911018007561/edgar.xml","form_type":"4"}},{"id":4125354,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-12-20T22:53:06.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":21471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. (\"Aisling\").  Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling.  The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling.  The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":3.7,"exercise_date":"2013-04-11","expiration_date":"2023-04-11","underlying":"Common Stock","underlying_shares":21471},"source":{"system":"sec-edgar","filing":"0001179110-17-015732","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911017015732/edgar.xml","form_type":"4"}},{"id":4125353,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T22:53:06.000Z","date":"2017-12-18","kind":"other","acquired":false,"shares":21471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. (\"Aisling\").  Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling.  The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling.  The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein."}],"balance_after":47,"source":{"system":"sec-edgar","filing":"0001179110-17-015732","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911017015732/edgar.xml","form_type":"4"}},{"id":4125352,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T22:53:06.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":21471,"price":3.7,"value":79442.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. (\"Aisling\").  Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling.  The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling.  The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein."}],"balance_after":21518,"source":{"system":"sec-edgar","filing":"0001179110-17-015732","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911017015732/edgar.xml","form_type":"4"}},{"id":4138333,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-08T21:42:57.000Z","date":"2017-12-05","kind":"other","acquired":true,"shares":38,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Aisling Capital II LP"}],"balance_after":47,"source":{"system":"sec-edgar","filing":"0001179110-17-015123","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000117911017015123/edgar.xml","form_type":"4"}},{"id":4288759,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-08T22:01:16.000Z","date":"2017-06-06","kind":"grant","acquired":true,"shares":53837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option terminates on the earlier of (i) June 7, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer."}],"balance_after":53837,"derivative":{"exercise_price":3.66,"expiration_date":"2027-06-06","underlying":"Common Stock","underlying_shares":53837},"source":{"system":"sec-edgar","filing":"0001193805-17-001054","document":"e616261_4-goldstein.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000119380517001054/e616261_4-goldstein.xml","form_type":"4"}},{"id":4350049,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-04-20T01:00:43.000Z","date":"2017-04-17","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017."}],"balance_after":14000,"derivative":{"exercise_price":38.96,"expiration_date":"2027-04-17","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0000950142-17-000823","document":"es1700532_4-goldstein.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095014217000823/es1700532_4-goldstein.xml","form_type":"4"}},{"id":4373867,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-23T20:37:07.000Z","date":"2017-03-22","kind":"sale","acquired":false,"shares":312642,"price":38.82,"value":12136762.44,"ownership":{"direct":false,"nature":"By Aisling Capital II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 to $41.29, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Aisling Capital II, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":837125,"source":{"system":"sec-edgar","filing":"0000950142-17-000629","document":"es1700432_4-goldstein.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095014217000629/es1700432_4-goldstein.xml","form_type":"4"}},{"id":4373866,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-23T20:37:07.000Z","date":"2017-03-21","kind":"sale","acquired":false,"shares":487358,"price":43.48,"value":21190325.84,"ownership":{"direct":false,"nature":"By Aisling Capital II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $46.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Aisling Capital II, LP (\"Aisling\"), and held indirectly by Aisling Capital Partners, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the \"Managers\") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":1149767,"source":{"system":"sec-edgar","filing":"0000950142-17-000629","document":"es1700432_4-goldstein.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095014217000629/es1700432_4-goldstein.xml","form_type":"4"}},{"id":4393157,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-09T18:21:55.000Z","date":"2017-03-08","kind":"sale","acquired":false,"shares":99900,"price":3.568,"value":356443.2,"ownership":{"direct":false,"nature":"By Aisling Capital II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital II, LP (\"Aisling\"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-17-000550","document":"es1700390_4-goldstein.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095014217000550/es1700390_4-goldstein.xml","form_type":"4"}},{"id":4393156,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-09T18:21:55.000Z","date":"2017-03-07","kind":"sale","acquired":false,"shares":50100,"price":3.5264,"value":176672.64,"ownership":{"direct":false,"nature":"By Aisling Capital II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are owned directly by Aisling Capital II, LP (\"Aisling\"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":99900,"source":{"system":"sec-edgar","filing":"0000950142-17-000550","document":"es1700390_4-goldstein.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095014217000550/es1700390_4-goldstein.xml","form_type":"4"}},{"id":4443433,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-02-17T01:14:54.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer."}],"balance_after":10000,"derivative":{"exercise_price":5,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193805-17-000280","document":"e615793_4-goldstein.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000119380517000280/e615793_4-goldstein.xml","form_type":"4"}},{"id":4443434,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-02-16T21:19:56.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests according to the following schedule: 1/12th of the shares vest at the end of each month over 12 months, beginning January 1, 2017."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These stock options are held by Dr. Goldstein for the benefit of Aisling Capital LLC. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":15000,"derivative":{"exercise_price":3,"expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950142-17-000381","document":"es1700309_4-goldstein.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095014217000381/es1700309_4-goldstein.xml","form_type":"4"}},{"id":4488776,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-18T21:17:31.000Z","date":"2017-01-13","kind":"sale","acquired":false,"shares":105460,"price":3.4,"value":358564.0,"ownership":{"direct":false,"nature":"By Aisling Capital II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.425, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Aisling Capital II, LP (\"Aisling\"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0000950142-17-000120","document":"es1700187_4-goldstein.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095014217000120/es1700187_4-goldstein.xml","form_type":"4"}},{"id":4496819,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-06T22:24:40.000Z","date":"2017-01-06","kind":"sale","acquired":false,"shares":437600,"price":3.64,"value":1592864.0,"ownership":{"direct":false,"nature":"By Aisling Capital II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $3.75, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Aisling Capital II, LP (\"Aisling\"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":255460,"source":{"system":"sec-edgar","filing":"0000950142-17-000081","document":"es1700159_4-goldstein.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095014217000081/es1700159_4-goldstein.xml","form_type":"4"}},{"id":4496818,"issuer":{"id":154249,"kind":"organization","name":"MELINTA THERAPEUTICS, INC. /NEW/","symbol":"MLNT"},"owners":[{"id":29909,"kind":"person","name":"GOLDSTEIN DOV A MD","position":1,"cik":"0001120478","reported_name":"GOLDSTEIN DOV A MD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-06T22:24:40.000Z","date":"2017-01-05","kind":"sale","acquired":false,"shares":500000,"price":3.2,"value":1600000.0,"ownership":{"direct":false,"nature":"By Aisling Capital II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.23, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Aisling Capital II, LP (\"Aisling\"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":693060,"source":{"system":"sec-edgar","filing":"0000950142-17-000081","document":"es1700159_4-goldstein.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120478/000095014217000081/es1700159_4-goldstein.xml","form_type":"4"}}]}